| BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors DR Buelow, B Bhatnagar, SJ Orwick, JY Jeon, ED Eisenmann, ... Blood advances 6 (17), 5049-5060, 2022 | 6 | 2022 |
| TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion ED Eisenmann, JC Stromatt, S Fobare, KM Huang, DR Buelow, S Orwick, ... Cancers 15 (1), 29, 2022 | 3 | 2022 |
| High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML DR Buelow, B Bhatnagar, JY Jeon, MZ Thomas, E Eisenmann, J Stromatt, ... Blood 138, 207, 2021 | 1 | 2021 |
| Preclinical Characterization of TP‐0903, a Novel Multikinase Inhibitor, in TP53 Mutant Acute Myeloid Leukemia E Eisenmann, S Fobare, K Huang, JY Jeon, R Weber, J Silvaroli, ... The FASEB Journal 35, 2021 | 1 | 2021 |
| Characterizing Imatinib’s Pharmacokinetics and Impact on Neuronal p-ERK Signaling S Kandalai, J Stromatt, E Ahmed, N Halloy, L Steenrod, J Hoak, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance) D Buelow, X Yang, D Nicolet, K Mrózek, K Krowiorz, R Bhayadia, ... Blood 142 (Supplement 1), 4126-4126, 2023 | | 2023 |
| Characterization of microenvironmental-mediated gilteritinib resistance in Acute Myeloid Leukemia using a Bmx knockout mouse model JC Stromatt, DR Buelow, SJ Orwick, E Eisenmann, NS Pabla, BW Blaser, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
